Press Release

Ipsen’s Annual Shareholders’ Meeting on June 4, 2009

Adoption of all resolutions submitted to the Shareholders’ vote

Paris, June 4, 2009 – Ipsen’s (Euronext: IPN) Annual Shareholders’ Meeting was held today, chaired by Jean-Luc BÉLINGARD, Chairman of the Board and Chief Executive Officer, in the presence of the Board of Directors and the Group’s management.

All resolutions submitted to the Shareholders’ Meeting were approved, including the distribution of a €0.70 dividend per share to be paid on June 12, 2009 (ex-dividend date June 9, 2009).

During the meeting, Jean-Luc BÉLINGARD and Claire GIRAUT, Executive Vice-President, Chief Financial Officer, presented Ipsen’s strategy, results and major events for 2008 as well as 2009 first quarter sales and outlook.

About Ipsen

Ipsen is an innovation-driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Its development strategy is based on a combination of specialty products, which are growth drivers, in targeted therapeutic areas (oncology, endocrinology and neurology), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 800 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partnerships. In 2008, Research and Development expenditure was about €183 million, close to 19% of consolidated sales, which amounted to €971 million while total revenues exceeded €1 billion. Ipsen’s shares are traded on Segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150). Ipsen’s shares are eligible to the “Service de Règlement Différé” (“SRD”) and the Group is part of the SBF 120 index. For more information on Ipsen, visit our website at www.ipsen.com.

For further information

Didier Véron
Director, Public Affairs and Corporate Communications
Tél.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
e-mail: didier.veron@ipsen.com

David Schilansky
Investor Relations and Financial Officer
Tél.: +33 (0)1 58 33 51 30
Fax: +33 (0)1 58 33 50 63
e-mail: david.schilansky@ipsen.com

Pierre Kemula
Investor Relations Manager
Tél.: +33 (0)1 58 33 60 08
Fax: +33 (0)1 58 33 50 63
e-mail: pierre.kemula@ipsen.com